LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | PI103 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1484 | 4223 | 0.3515 | 0.0293 |
| SK-BR-3 | PLX-4720 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3476 | 4223 | 0.8232 | 0.7353 |
| SK-BR-3 | QL-X-138 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1775 | 4223 | 0.4204 | 0.1325 |
| SK-BR-3 | QL-XII-47 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1266 | 4223 | 0.2999 | -0.0478 |
| SK-BR-3 | Radicicol | 3.33 | uM | LJP5 | 72 | hr | 1401 | 1603 | 4223 | 0.3796 | 0.0714 |
| SK-BR-3 | Radicicol | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1469 | 4223 | 0.3480 | 0.0242 |
| SK-BR-3 | Seliciclib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3235 | 4223 | 0.7660 | 0.6498 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 4351 | 4223 | 1.0304 | 1.0456 |
| SK-BR-3 | XL147 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 4818 | 4223 | 1.1409 | 1.2110 |
| SK-BR-3 | Saracatinib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 3617 | 4223 | 0.8566 | 0.7854 |
| SK-BR-3 | Selumetinib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 4365 | 4223 | 1.0338 | 1.0505 |
| SK-BR-3 | Sirolimus | 3.33 | uM | LJP6 | 72 | hr | 1401 | 2546 | 4223 | 0.6030 | 0.4059 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 4352 | 4223 | 1.0306 | 1.0458 |
| SK-BR-3 | SU11274 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3915 | 4223 | 0.9272 | 0.8911 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 2865 | 4223 | 0.6784 | 0.5187 |
| SK-BR-3 | TGX221 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 4210 | 4223 | 0.9970 | 0.9955 |
| SK-BR-3 | Torin1 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1400 | 4223 | 0.3316 | -0.0004 |
| SK-BR-3 | Torin2 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 1064 | 4223 | 0.2520 | -0.1196 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 1428 | 4223 | 0.3383 | 0.0096 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3487 | 4223 | 0.8258 | 0.7392 |
| SK-BR-3 | TWS119 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3029 | 4223 | 0.7173 | 0.5768 |
| SK-BR-3 | Vemurafenib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3883 | 4223 | 0.9196 | 0.8797 |
| SK-BR-3 | Withaferin A | 3.33 | uM | LJP5 | 72 | hr | 1401 | 931 | 4223 | 0.2206 | -0.1665 |
| SK-BR-3 | Withaferin A | 3.33 | uM | LJP6 | 72 | hr | 1401 | 985 | 4223 | 0.2334 | -0.1474 |
| SK-BR-3 | WYE-125132 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1571 | 4223 | 0.3722 | 0.0603 |